Trial of Solanezumab in Preclinical Alzheimer’s Disease
医学
肿瘤科
作者
Reisa A. Sperling,Michael Donohue,Rema Raman,Michael S. Rafii,Keith Johnson,Colin L. Masters,Christopher H. van Dyck,Takeshi Iwatsubo,Gad A. Marshall,R. Yaari,Michele Mancini,Karen C. Holdridge,Michael Case,John R. Sims,Paul Aisen
Solanezumab, which targets monomeric amyloid in persons with elevated brain amyloid levels, did not slow cognitive decline as compared with placebo over a period of 240 weeks in persons with preclinical Alzheimer's disease. (Funded by the National Institute on Aging and others; A4 ClinicalTrials.gov number, NCT02008357.).
PDF的下载单位、IP信息已删除
(2025-6-4)
大力的灵雁
湖工大保卫处
GingerF
Criminology34
戒骄戒躁戒熬夜
愔愔
OsamaKareem
L_
无极微光
斯文的白玉
MingH
贪玩的秋柔
雨jia
缓慢怜菡
YifanWang
自然思烟
学术文献互助
张欢馨
Hayat
loii
皖公网安备34019202002308
